VANCOUVER, British Columbia, May 12, 2005 (PRIMEZONE) -- Dr. Geraldine Deliencourt, of the University of Rouen, has informed ProtoKinetix (OTCBB:PKTX) that their laboratory has completed the engineering of the dimeric class of the synthetic AFGP molecule. A dimeric molecule is constructed in such a way as to provide two active sites thus enhancing the characteristics of the native molecule. Native AFGP has been proven to be a natural source of cellular and tissue antifreeze. Extensive tests around the world have proven this molecule to be a highly effective agent in the preservation of sensitive human cells.
ProtoKinetix has successfully tested the monomeric synthetic AFGP on a wide range of human cells and tissue lines for stability, toxicity and efficacy. Based on the positive results the Company has received to date, ProtoKinetix is confident that this new synthetic formulation will expand the applications, effectiveness and commercialization of this family of versatile molecules.
About ProtoKinetix:
ProtoKinetix Inc. is a scientific development company whose mission is the advancement of human health care. The Company's first entry into the commercial market place will be the launch of the first synthetically replicated antifreeze glycoprotein (AFGP). PKTX has developed a unique business model that brings together a vast pool of world recognized intellectual talent in a networked environment. This integrated scientific approach combines the disciplines of physics, chemistry and molecular biology in order to fast track product development.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.
On behalf of the Board of Directors, Dr. John Todd, President